Physician profile
Lauren E Kirby
NPI 1164813317
$3,990.99
in general payments reported to CMS, 2019-2025
31 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $913 · 2022: $554 · 2023: $433 · 2024: $653 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441 · Education: $82.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.37 |
| Education | $82.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $662.57 | 2021-2025 | |
| Abbvie INC. | $543.29 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.17 | 2021-2025 | Jardiance |
| Amgen INC. | $327.87 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $307.30 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $266.87 | 2021-2025 | Mounjaro, Jardiance |
| Corcept Therapeutics | $191.27 | 2025 | Korlym |
| Pfizer INC. | $149.67 | 2021-2025 | |
| Astellas Pharma US INC | $111.85 | 2023-2025 | Veozah |
| Novo Nordisk INC | $108.31 | 2021-2025 | Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $86.21 | 2021-2022 | |
| Glaxosmithkline, LLC. | $85.87 | 2021-2025 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $82.55 | 2021-2022 | |
| Dexcom, INC. | $72.01 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $68.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $61.63 | 2024-2025 | Proclaim |
| Merck Sharp & Dohme LLC | $48.00 | 2021-2025 | Verquvo |
| Clarus Therapeutics INC. | $47.09 | 2021 | |
| Nestle Healthcare Nutrition INC. | $44.10 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.06 | 2025 | Caplyta |
| Antares Pharma, INC. | $34.38 | 2024-2025 | Xyosted |
| Tolmar, INC. | $27.46 | 2024 | |
| Sequel Med Tech, LLC | $19.94 | 2025 | Twiist |
| Phathom Pharmaceuticals, INC. | $18.98 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $18.79 | 2024 | Nexletol |
| Medtronic, INC. | $16.07 | 2025 | Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $15.80 | 2022 | |
| Eisai INC. | $14.80 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.42 | 2024 | Xifaxan, Trulance |
| Si-Bone, INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Kirby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.